Revonto ™ (dantrolene sodium for injection)

Call (877) 411-USWM (8796)

Watch the Video

Ordering Information

Ordering Information

US WorldMeds offers a minimum order of 1 carton (6 vials), a free reminder service and several easy ways to order Revonto. It is available on your GPO contract as a dropship via your wholesaler/distributor. Below you will find the item numbers associated with Revonto.

For more information call: (877) 411-USWM (8796)
After Hours/Emergency Order Information: (866) 916-0581

US WorldMeds Label
NovaPlus Label
ORDERING REVONTO
NDC# 78670-003-67
20 mg Revonto
Cartons of 6 vials, 65 mL vial
Click the Revonto label for larger view
(Click on label for larger view.)
Order Number Distributor/Wholesaler Customer Service
10258268 AmerisourceBergen (ABC) 844-222-2273
10257588 Besse Medical 800-543-2111
700367 Capital Wholesale 800-282-2754
5718788 Cardinal Health (CAH) 800-926-3161
431761 CuraScript 877-599-7748
1402640 Henry Schein 866-234-6507
1189986 McKesson Medical-Surgical 855-571-2100
2322345 McKesson Specialty Health (McK) 855-625-4677
REVO/6VI Medical Purchasing Solutions 888-894-2487
21048 Morris & Dickson (M&D) 800-388-3833
000367 Southern Anesthesia 800-624-5926

Please see full prescribing information for Revonto.

 

Indication

Revonto is indicated, along with appropriate supportive measures, for the management of fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. It is also indicated preoperatively and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.

Important Safety Information

The use of Revonto in the management of malignant hyperthermia crisis is not a substitute for previously known supportive measures. These measures must be individualized, but it will usually be necessary to discontinue the suspect triggering agents, attend to increased oxygen requirements, manage the metabolic acidosis, institute cooling when necessary, monitor urinary output, and monitor for electrolyte imbalance. Patients who receive i.v. dantrolene sodium preoperatively should have vital signs monitored.

If patients judged malignant hyperthermia susceptible are administered dantrolene sodium preoperatively, anesthetic preparation must still follow a standard malignant hyperthermia susceptible regimen, including the avoidance of known triggering agents. Monitoring for early clinical and metabolic signs of malignant hyperthermia is indicated because attenuation of malignant hyperthermia, rather than prevention, is possible.

Despite initial satisfactory response to i.v. dantrolene there have been reports of fatality, which involve patients who could not be weaned from dantrolene after initial treatment. The administration of i.v. dantrolene is associated with loss of grip strength and weakness in the legs, as well as drowsiness and dizziness. There have been reports of thrombophlebitis following administration of intravenous dantrolene. Tissue necrosis secondary to extravasation has been reported. Injection site reactions (pain, erythema, swelling), commonly due to extravasation, have been reported. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy.

To report SUSPECTED ADVERSE REACTIONS contact USWM, LLC at 1-888-900-8796 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088)
or http://www.FDA.gov/medwatch/.

For additional information, see full prescribing information for Revonto.